Lexaria Bioscience Corp. to Present at H.C. Wainwright Global Investment Conference

Kelowna, British Columbia — September 4, 2026 — Leads & Copy — Lexaria Bioscience Corp. (NASDAQ: LEXX), a leader in oral drug delivery platforms, announced its participation in the 28th Annual H.C. Wainwright Global Investment Conference. The conference is scheduled to take place from September 14th to September 16th, 2026, in New York City.

Richard Christopher, CEO of Lexaria Bioscience Corp., will present the company's latest developments and engage in one-on-one meetings with investors during the event. The company presentation will also be accessible online via a provided link.

Accredited investors interested in meeting with the Lexaria management team can connect with their H.C. Wainwright representative or send an email to meetings@hcwco.com.

Lexaria Bioscience Corp. is known for its DehydraTECH™ technology, a patented drug delivery formulation and processing platform designed to enhance the bloodstream entry of various drugs through oral administration. DehydraTECH™ has demonstrated the capacity to improve bio-absorption, minimize side effects, and facilitate more effective delivery of certain drugs across the blood-brain barrier. The company operates a licensed in-house research laboratory and possesses a substantial intellectual property portfolio, holding 66 granted patents with additional patent applications pending globally.

Further details about Lexaria Bioscience Corp. and its DehydraTECH™ technology can be found on its website.

Source: Lexaria Bioscience Corp.